Relay Therapeutics (RLAY) Capital Expenditures (2019 - 2025)

Relay Therapeutics (RLAY) has 7 years of Capital Expenditures data on file, last reported at $1000.0 in Q4 2025.

• Capital Expenditures for Q4 2025 came in at $1000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $410000.0 (down 79.68% YoY), and the FY2025 annual result was $410000.0, down 79.68% from the prior year.
• Capital Expenditures advanced to $1000.0 in Q4 2025 per RLAY's latest filing, from -$1000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $2.8 million in Q1 2022 and troughed at -$1000.0 in Q3 2025.
• A 5-year average of $1.0 million and a median of $880000.0 in 2021 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2022 and 2025: Capital Expenditures jumped 2694.0% in 2022, then plunged 100.44% in 2025.
• A 5-year view of Capital Expenditures shows it stood at $880000.0 in 2021, then jumped by 163.18% to $2.3 million in 2022, then plunged by 94.91% to $118000.0 in 2023, then surged by 92.37% to $227000.0 in 2024, then plunged by 99.56% to $1000.0 in 2025.
• Business Quant data shows RLAY's Capital Expenditures at $1000.0 in Q4 2025, -$1000.0 in Q3 2025, and $26000.0 in Q2 2025.